STAAR Surgical Company $STAA is Defender Capital LLC.’s 10th Largest Position

Defender Capital LLC. trimmed its stake in STAAR Surgical Company (NASDAQ:STAA) by 3.4% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 695,764 shares of the medical instruments supplier’s stock after selling 24,768 shares during the quarter. STAAR Surgical accounts for 4.0% of Defender Capital LLC.’s portfolio, making the stock its 10th largest position. Defender Capital LLC.’s holdings in STAAR Surgical were worth $11,675,000 as of its most recent SEC filing.

Other hedge funds have also made changes to their positions in the company. Wealth Enhancement Advisory Services LLC lifted its position in shares of STAAR Surgical by 75.4% in the first quarter. Wealth Enhancement Advisory Services LLC now owns 21,234 shares of the medical instruments supplier’s stock worth $374,000 after purchasing an additional 9,125 shares in the last quarter. Pinnacle Investment Management Ltd purchased a new stake in shares of STAAR Surgical in the first quarter worth approximately $1,155,000. Strs Ohio purchased a new stake in shares of STAAR Surgical in the first quarter worth approximately $190,000. Assenagon Asset Management S.A. lifted its position in shares of STAAR Surgical by 213.1% in the second quarter. Assenagon Asset Management S.A. now owns 164,088 shares of the medical instruments supplier’s stock worth $2,753,000 after purchasing an additional 111,686 shares in the last quarter. Finally, Caxton Associates LLP purchased a new stake in shares of STAAR Surgical in the first quarter worth approximately $1,051,000. 96.70% of the stock is owned by hedge funds and other institutional investors.

STAAR Surgical Stock Up 2.1%

Shares of STAA stock opened at $27.25 on Tuesday. STAAR Surgical Company has a 12 month low of $13.50 and a 12 month high of $33.28. The business’s 50 day moving average is $27.35 and its two-hundred day moving average is $21.03. The company has a market cap of $1.34 billion, a PE ratio of -14.12 and a beta of 0.82.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Canaccord Genuity Group increased their price target on shares of STAAR Surgical from $20.00 to $28.00 and gave the stock a “hold” rating in a research report on Wednesday, August 6th. Mizuho raised their price objective on shares of STAAR Surgical from $17.00 to $18.00 and gave the company a “neutral” rating in a research report on Wednesday, July 16th. Piper Sandler raised shares of STAAR Surgical to a “hold” rating in a research report on Wednesday, June 18th. Weiss Ratings reaffirmed a “sell (d)” rating on shares of STAAR Surgical in a research report on Wednesday, October 8th. Finally, Stifel Nicolaus set a $28.00 price objective on shares of STAAR Surgical and gave the company a “hold” rating in a research report on Thursday, August 7th. Ten analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, STAAR Surgical presently has a consensus rating of “Reduce” and a consensus target price of $20.67.

STAAR Surgical Company Profile

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia.